151 related articles for article (PubMed ID: 28703861)
21. In vitro quality of platelets during prolonged storage after washing with three platelet additive solutions.
Tynngård N; Trinks M; Berlin G
Vox Sang; 2012 Jan; 102(1):32-9. PubMed ID: 21534983
[TBL] [Abstract][Full Text] [Related]
22. pH value promotes growth of Staphylococcus epidermidis in platelet concentrates.
Störmer M; Kleesiek K; Dreier J
Transfusion; 2008 May; 48(5):836-46. PubMed ID: 18298602
[TBL] [Abstract][Full Text] [Related]
23. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
Paglia G; Sigurjónsson ÓE; Rolfsson Ó; Hansen MB; Brynjólfsson S; Gudmundsson S; Palsson BO
Transfusion; 2015 Feb; 55(2):301-13. PubMed ID: 25156572
[TBL] [Abstract][Full Text] [Related]
24. The effect of gamma irradiation on the quality of apheresis platelets during storage for 7 days.
Tynngård N; Studer M; Lindahl TL; Trinks M; Berlin G
Transfusion; 2008 Aug; 48(8):1669-75. PubMed ID: 18482187
[TBL] [Abstract][Full Text] [Related]
25. The effect of gamma irradiation on platelet redox state during storage.
Nodeh FK; Hosseini E; Ghasemzadeh M
Transfusion; 2021 Feb; 61(2):579-593. PubMed ID: 33231307
[TBL] [Abstract][Full Text] [Related]
26. The influence of simulated shipping conditions (24- or 30-hr interruption of agitation) on the in vitro properties of apheresis platelets during 7-day storage.
Wagner SJ; Vassallo R; Skripchenko A; Einarson M; Seetharaman S; Moroff G
Transfusion; 2008 Jun; 48(6):1072-80. PubMed ID: 18373503
[TBL] [Abstract][Full Text] [Related]
27. Donor variation in stored platelets: Higher metabolic rates of platelets are associated with mean platelet volume, activation and donor health.
Bontekoe IJ; van der Meer PF; Tanis BC; de Korte D; Verhoeven AJ; Raat NJH; Specht PAC; Mik EG; Klei TRL
Transfusion; 2022 Dec; 62(12):2609-2620. PubMed ID: 36278429
[TBL] [Abstract][Full Text] [Related]
28. Effects of immediate or delayed addition of platelet additive solution on the in vitro quality of apheresis platelets.
Ringwald J; Tully S; Geier C; Hauck B; Weiss D; Callaert M; Eckstein R
Transfusion; 2012 Jun; 52(6):1237-44. PubMed ID: 22070790
[TBL] [Abstract][Full Text] [Related]
29. Preparation and storage of white blood cell-reduced split apheresis platelet concentrates for pediatric use.
van der Meer PF; Vrielink H; Pietersz RN
Transfusion; 2005 Feb; 45(2):223-7. PubMed ID: 15660831
[TBL] [Abstract][Full Text] [Related]
30. PLTs of blood group A1 donors express increased surface A antigen owing to apheresis and prolonged storage.
Julmy F; Achermann F; Schulzki T; Carrel T; Nydegger U
Transfusion; 2003 Oct; 43(10):1378-85. PubMed ID: 14507268
[TBL] [Abstract][Full Text] [Related]
31. Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality.
Ringwald J; Walz S; Zimmermann R; Zingsem J; Strasser E; Weisbach V; Eckstein R
Vox Sang; 2005 Jul; 89(1):11-8. PubMed ID: 15938735
[TBL] [Abstract][Full Text] [Related]
32. Fully automated processing of buffy-coat-derived pooled platelet concentrates.
Janetzko K; Klüter H; van Waeg G; Eichler H
Transfusion; 2004 Jul; 44(7):1052-8. PubMed ID: 15225247
[TBL] [Abstract][Full Text] [Related]
33. Impact of different hold time before addition of platelet additive solution on the in vitro quality of apheresis platelets.
Ringwald J; Haager B; Krex D; Zimmermann R; Strasser E; Antoon M; De Schrijver E; Eckstein R
Transfusion; 2006 Jun; 46(6):942-8. PubMed ID: 16734810
[TBL] [Abstract][Full Text] [Related]
34. In vitro function of platelets treated with ultraviolet C light for pathogen inactivation: a comparative study with nonirradiated and gamma-irradiated platelets.
Tynngård N; Trinks M; Berlin G
Transfusion; 2015 Jun; 55(6):1169-77. PubMed ID: 25524519
[TBL] [Abstract][Full Text] [Related]
35. Frequently used plateletpheresis techniques result in variable target yields and platelet recruitment of donors.
Strasser EF; Schuster M; Egler K; Bauer J; Weisbach V; Ringwald J; Zimmermann R; Zingsem J; Eckstein R
Transfusion; 2005 May; 45(5):788-97. PubMed ID: 15847670
[TBL] [Abstract][Full Text] [Related]
36. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
37. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylserine exposure in platelet concentrates during the storage period: differences between the platelets collected with different cell separators.
Lai M; Rumi C; D'Onofrio G; Puggioni PL; Menichella G; Candido A; Leone G
Transfus Apher Sci; 2002 Dec; 27(3):239-45. PubMed ID: 12509219
[TBL] [Abstract][Full Text] [Related]
39. Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets.
Krailadsiri P; Seghatchian J
Vox Sang; 2000; 78(3):171-5. PubMed ID: 10838518
[TBL] [Abstract][Full Text] [Related]
40. Soluble glycoprotein V as a quality marker of platelet concentrates stressed by transportation.
Javela K; Eronen J; Sarna S; Kekomäki R
Transfusion; 2005 Sep; 45(9):1504-11. PubMed ID: 16131384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
